Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

v3.22.1
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
Common Stock
Change in cumulative translation adjustment
Common Stock
Additional Paid-in Capital
Change in cumulative translation adjustment
Additional Paid-in Capital
Accumulated Deficit
Change in cumulative translation adjustment
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Change in cumulative translation adjustment
Accumulated Other Comprehensive Income (Loss)
Equity of Non-controlling Interest
Change in cumulative translation adjustment
Total
Stockholders' equity, Beginning balance at Feb. 02, 2019   $ 68,000   $ 442,808,000   $ (377,925,000)         $ 64,951,000
Common Stock, Shares, Outstanding period beginning at Feb. 02, 2019   6,791,934                  
Net loss   $ 0   0   (56,296,000)   $ 0 $ 0   (56,296,000)
Repurchases of common stock   $ 0   0   0          
Repurchases of common stock (in shares)   0                  
Common stock issuances pursuant to equity compensation awards   $ 2,000   (41,000)   0         (39,000)
Common stock issuances pursuant to equity compensation awards (in shares)   225,293                  
Share-based payment compensation   $ 0   2,204,000   0         2,204,000
Common stock issuances pursuant to business acquisitions, Value   $ 4,000   1,852,000   0         1,856,000
Common stock issuances pursuant to business acquisitions, Shares   391,000                  
Common stock and warrant issuance   $ 8,000   6,010,000   0         6,018,000
Common stock and warrant issuance (in shares)   800,000                  
Stockholders' equity, ending balance at Feb. 01, 2020   $ 82,000   452,833,000   (434,221,000)         18,694,000
Common Stock, Shares, Outstanding period end at Feb. 01, 2020   8,208,227                  
Net loss   $ 0   0   (13,234,000)         (13,234,000)
Common stock issuances pursuant to equity compensation awards   $ 1,000   (14,000)   0         (13,000)
Common stock issuances pursuant to equity compensation awards (in shares)   99,822                  
Exercise of warrants   $ 1,000   (1,000)   0          
Exercise of warrants (in shares)   114,698                  
Share-based payment compensation   $ 0   1,960,000   0         1,960,000
Common stock and warrant issuance   $ 46,000   19,597,000   0         19,643,000
Common stock and warrant issuance (in shares)   4,596,314                  
Stockholders' equity, ending balance at Jan. 30, 2021   $ 130,000   474,375,000   (447,455,000)         $ 27,050,000
Common Stock, Shares, Outstanding period end at Jan. 30, 2021   13,019,061                 13,019,061
Net loss   $ 0   0   (22,008,000)     (1,018,000)   $ (23,026,000)
Common stock issuances pursuant to equity compensation awards   $ 4,000   (206,000)   0         (202,000)
Common stock issuances pursuant to equity compensation awards (in shares)   413,626                  
Share-based payment compensation - restricted stock   $ 0   3,146,000   0         3,146,000
Share-based payment compensation - options   0   174,000   0         174,000
Common stock and warrant issuance   $ 81,000   61,138,000   0         61,219,000
Common stock and warrant issuance (in shares)   8,138,700                  
Investment of non-controlling interest   $ 0   0   0     3,430,000   3,430,000
Stockholders' equity, ending balance at Jan. 29, 2022 $ 0 $ 216,000 $ 0 $ 538,627,000 $ 0 $ (469,463,000) $ (2,428,000) $ (2,428,000) $ 2,412,000 $ (2,428,000) $ 69,363,000
Common Stock, Shares, Outstanding period end at Jan. 29, 2022   21,571,387                 21,571,387